AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq: AFFX) announced today that Wyeth (NYSE: WYE) has signed another agreement with Affymetrix to use GeneChip� microarray technology for three more years, further extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. Wyeth was one of the first pharmaceutical companies to apply genomics in clinical research. The company will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient�s response to therapy. The latest GeneChip technology enables them to more accurately classify disease, predict clinical progression and determine likelihoods of treatment success in ways never before possible. �Wyeth has been a pioneer in demonstrating the power of Affymetrix microarray technology in the entire drug discovery and development process,� said Chip Leveille, vice president, Pharmaceutical Business Unit at Affymetrix. �We anticipate that a better understanding of human genetic variations and the ability to look at the entire genome in greater detail will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster.� About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip� technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the agreement between Affymetrix and Wyeth discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. Affymetrix Inc. (Nasdaq: AFFX) announced today that Wyeth (NYSE: WYE) has signed another agreement with Affymetrix to use GeneChip(R) microarray technology for three more years, further extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. Wyeth was one of the first pharmaceutical companies to apply genomics in clinical research. The company will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient's response to therapy. The latest GeneChip technology enables them to more accurately classify disease, predict clinical progression and determine likelihoods of treatment success in ways never before possible. "Wyeth has been a pioneer in demonstrating the power of Affymetrix microarray technology in the entire drug discovery and development process," said Chip Leveille, vice president, Pharmaceutical Business Unit at Affymetrix. "We anticipate that a better understanding of human genetic variations and the ability to look at the entire genome in greater detail will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster." About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the agreement between Affymetrix and Wyeth discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.